KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $73.0 million.

  • Halozyme Therapeutics' Other Operating Expenses rose 8.66% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.1 million, marking a year-over-year increase of 9.31%. This contributed to the annual value of $230.5 million for FY2024, which is 13.40% down from last year.
  • Halozyme Therapeutics' Other Operating Expenses amounted to $73.0 million in Q3 2025, which was up 13.85% from $64.1 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Other Operating Expenses registered a high of $75.2 million during Q3 2023, and its lowest value of $15.9 million during Q1 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $66.2 million (2025), whereas its average is $63.6 million.
  • Data for Halozyme Therapeutics' Other Operating Expenses shows a peak YoY increase of 301.01% (in 2021) and a maximum YoY decrease of 17.83% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Other Operating Expenses stood at $21.6 million in 2021, then spiked by 116.20% to $46.7 million in 2022, then skyrocketed by 50.11% to $70.1 million in 2023, then declined by 14.62% to $59.8 million in 2024, then increased by 8.66% to $73.0 million in 2025.
  • Its Other Operating Expenses stands at $73.0 million for Q3 2025, versus $64.1 million for Q2 2025 and $66.2 million for Q1 2025.